THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 98 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 6.05 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $214,760 | -25.4% | 23,942 | -6.5% | 0.00% | 0.0% |
Q4 2023 | $287,856 | +18.5% | 25,610 | -9.0% | 0.00% | -50.0% |
Q3 2023 | $242,848 | -21.0% | 28,140 | -5.2% | 0.00% | 0.0% |
Q2 2023 | $307,271 | -10.1% | 29,688 | -5.8% | 0.00% | 0.0% |
Q1 2023 | $341,949 | -1.3% | 31,516 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $346,586 | +11.8% | 30,890 | +1.1% | 0.00% | 0.0% |
Q3 2022 | $310,000 | +13.6% | 30,568 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $273,000 | -4.2% | 30,136 | +1.2% | 0.00% | 0.0% |
Q1 2022 | $285,000 | -19.0% | 29,790 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $352,000 | +44.9% | 31,887 | -2.9% | 0.00% | +100.0% |
Q3 2021 | $243,000 | -44.0% | 32,840 | +9.9% | 0.00% | 0.0% |
Q2 2021 | $434,000 | -21.8% | 29,873 | +9.9% | 0.00% | -50.0% |
Q1 2021 | $555,000 | +15.1% | 27,188 | +0.3% | 0.00% | 0.0% |
Q4 2020 | $482,000 | +18.4% | 27,116 | -1.4% | 0.00% | 0.0% |
Q3 2020 | $407,000 | -31.0% | 27,505 | -2.2% | 0.00% | -33.3% |
Q2 2020 | $590,000 | -12.1% | 28,131 | -3.1% | 0.00% | -25.0% |
Q1 2020 | $671,000 | -7.4% | 29,034 | +3.7% | 0.00% | +33.3% |
Q4 2019 | $725,000 | +33.3% | 27,998 | +0.3% | 0.00% | +50.0% |
Q3 2019 | $544,000 | +18.5% | 27,922 | -0.7% | 0.00% | 0.0% |
Q2 2019 | $459,000 | -26.7% | 28,118 | +1.9% | 0.00% | 0.0% |
Q1 2019 | $626,000 | -14.1% | 27,603 | -3.1% | 0.00% | -33.3% |
Q4 2018 | $729,000 | -21.5% | 28,498 | +0.2% | 0.00% | 0.0% |
Q3 2018 | $929,000 | +46.8% | 28,429 | +1.8% | 0.00% | +50.0% |
Q2 2018 | $633,000 | -3.5% | 27,916 | +3.1% | 0.00% | 0.0% |
Q1 2018 | $656,000 | -16.4% | 27,069 | -3.8% | 0.00% | -33.3% |
Q4 2017 | $785,000 | -18.1% | 28,134 | +0.5% | 0.00% | 0.0% |
Q3 2017 | $959,000 | -7.1% | 28,000 | +8.1% | 0.00% | -25.0% |
Q2 2017 | $1,032,000 | +15.4% | 25,906 | +6.7% | 0.00% | +33.3% |
Q1 2017 | $894,000 | +34.4% | 24,276 | +16.4% | 0.00% | 0.0% |
Q4 2016 | $665,000 | -99.9% | 20,859 | -0.3% | 0.00% | 0.0% |
Q3 2016 | $757,887,000 | +60.0% | 20,913 | +0.2% | 0.00% | +50.0% |
Q2 2016 | $473,790,000 | +68.6% | 20,881 | +39.8% | 0.00% | +100.0% |
Q1 2016 | $281,000,000 | +14.7% | 14,935 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $245,000,000 | +149290.2% | 14,935 | -0.2% | 0.00% | 0.0% |
Q3 2015 | $164,000 | -99.9% | 14,961 | +0.1% | 0.00% | 0.0% |
Q2 2015 | $194,571,000 | -24.2% | 14,944 | +1.0% | 0.00% | 0.0% |
Q1 2015 | $256,693,000 | +16.3% | 14,795 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $220,741,000 | -37.7% | 14,795 | -3.8% | 0.00% | -50.0% |
Q3 2014 | $354,486,000 | -27.8% | 15,379 | -0.1% | 0.00% | 0.0% |
Q2 2014 | $490,665,000 | – | 15,391 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |